North Potomac, MD, United States of America

Krishnan Sampathkumar

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Krishnan Sampathkumar: Innovator in Pharmaceutical Compositions

Introduction

Krishnan Sampathkumar is a notable inventor based in North Potomac, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions for cancer treatment. With a total of 2 patents to his name, his work is paving the way for advancements in medical therapies.

Latest Patents

Sampathkumar's latest patents include groundbreaking pharmaceutical compositions. The first patent focuses on a PD-1 antibody, known as retifanlimab, which is designed for storage and administration. This composition includes buffering agents and is intended for the treatment of cancers expressing PD-L1. The second patent revolves around a HER2/neu antibody, margetuximab, which is also formulated for stability and effectiveness in treating HER2-positive cancers, including breast and gastric cancers.

Career Highlights

Krishnan Sampathkumar is currently associated with Macrogenics, Inc., a company dedicated to developing innovative cancer therapies. His work at Macrogenics has been instrumental in advancing the understanding and treatment of various cancers through targeted therapies.

Collaborations

Sampathkumar collaborates with esteemed colleagues such as Yan Zhou and David Lee Farb. Their combined expertise contributes to the innovative research and development efforts at Macrogenics.

Conclusion

Krishnan Sampathkumar's contributions to pharmaceutical compositions highlight his role as a key innovator in cancer treatment. His patents reflect a commitment to improving therapeutic options for patients, showcasing the importance of innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…